Kalamazoo Community Foundation Report issue

Foundation Phase 4

Organization Overview

First Clinical Trial
2016
NCT02726035
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

naltrexone (revia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Self-Injurious Behavior (Phase 4)

Self Mutilation (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1